JP6419347B2 - 胃腸疾患治療用医薬組成物 - Google Patents

胃腸疾患治療用医薬組成物 Download PDF

Info

Publication number
JP6419347B2
JP6419347B2 JP2017540683A JP2017540683A JP6419347B2 JP 6419347 B2 JP6419347 B2 JP 6419347B2 JP 2017540683 A JP2017540683 A JP 2017540683A JP 2017540683 A JP2017540683 A JP 2017540683A JP 6419347 B2 JP6419347 B2 JP 6419347B2
Authority
JP
Japan
Prior art keywords
particle size
pharmaceutical composition
sucralfate
average particle
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017540683A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018503672A (ja
Inventor
チョ・ヨンホ
イ・ジュンウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daewoong Pharmaceutical Co Ltd
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55169799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6419347(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of JP2018503672A publication Critical patent/JP2018503672A/ja
Application granted granted Critical
Publication of JP6419347B2 publication Critical patent/JP6419347B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017540683A 2015-01-30 2016-01-28 胃腸疾患治療用医薬組成物 Active JP6419347B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20150015339 2015-01-30
KR10-2015-0015339 2015-01-30
KR1020150147513A KR101583452B1 (ko) 2015-01-30 2015-10-22 위장질환 치료용 의약 조성물
KR10-2015-0147513 2015-10-22
PCT/KR2016/000935 WO2016122226A2 (en) 2015-01-30 2016-01-28 A pharmaceutical composition for treating gastrointestinal diseases

Publications (2)

Publication Number Publication Date
JP2018503672A JP2018503672A (ja) 2018-02-08
JP6419347B2 true JP6419347B2 (ja) 2018-11-07

Family

ID=55169799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017540683A Active JP6419347B2 (ja) 2015-01-30 2016-01-28 胃腸疾患治療用医薬組成物

Country Status (19)

Country Link
EP (1) EP3250199A4 (es)
JP (1) JP6419347B2 (es)
KR (2) KR101583452B1 (es)
CN (1) CN107205947B (es)
AR (1) AR105413A1 (es)
CL (1) CL2017001680A1 (es)
CO (1) CO2017006222A2 (es)
EA (1) EA032385B9 (es)
EC (1) ECSP17038599A (es)
GE (1) GEP20196941B (es)
MA (1) MA41432A (es)
MX (1) MX2017007567A (es)
MY (1) MY195824A (es)
PE (1) PE20171340A1 (es)
PH (1) PH12017550051A1 (es)
SA (1) SA517382016B1 (es)
TW (1) TWI635859B (es)
UA (1) UA116517C2 (es)
WO (1) WO2016122226A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101988479B1 (ko) 2017-10-11 2019-09-24 (주)휴럼 리트세노라이드를 유효성분으로 하는 헬리코박터 파이로리 균주로부터 유래되는 위장질환 예방 및 치료용 약학 조성물
JP2021518422A (ja) * 2018-04-13 2021-08-02 サムヤン バイオファーマシューティカルズ コーポレイションＳａｍｙａｎｇ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ レナリドミドを含む医薬組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE81011T1 (de) * 1987-03-09 1992-10-15 Procter & Gamble Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
US4990610A (en) * 1988-08-25 1991-02-05 Applied Analytical Industries, Inc. Method for preparing high potency sucralfate
EP0403048A3 (en) * 1989-06-14 1991-01-30 Warner-Lambert Company Medicated compositions containing sucralfate and processes for their production
KR970006083B1 (ko) * 1992-01-22 1997-04-23 주식회사 대웅제약 위장질환 치료용 의약 조성물
KR100264547B1 (ko) * 1994-04-26 2000-12-01 나가야마 오사무 수크랄페이트의용융조립제제및그의제조방법
JPH0879097A (ja) * 1994-09-01 1996-03-22 Matsushita Electric Ind Co Ltd 携帯無線機
KR970006083A (ko) 1995-07-06 1997-02-19 한승준 자동차용 카울부의 와이어 고정장치 취부구조
JP2001513570A (ja) * 1997-08-25 2001-09-04 ザ、プロクター、エンド、ギャンブル、カンパニー 上部胃腸管不調治療用複合製剤
AU4655199A (en) 1999-06-21 2001-01-09 Dae Woong Pharmaceutical Co., Ltd. Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate
JP2006076956A (ja) * 2004-09-10 2006-03-23 Taiyo Yakuhin Kogyo Kk 胃炎の治療・予防用配合剤
JP5516401B2 (ja) * 2008-07-01 2014-06-11 ライオン株式会社 固形内服製剤
KR20110105223A (ko) * 2010-03-18 2011-09-26 일양약품주식회사 일라프라졸 및 수크랄페이트와 비스무스 제제의 혼합물을 함유하는 위장질환을 예방 또는 치료하기 위한 경구용 약제 조성물
KR20140072673A (ko) 2012-12-05 2014-06-13 (주)한국파비스제약 경구용 위장질환 치료를 위한 정제

Also Published As

Publication number Publication date
MX2017007567A (es) 2017-10-19
KR101583452B9 (ko) 2022-05-02
EP3250199A4 (en) 2018-08-08
AR105413A1 (es) 2017-10-04
MA41432A (fr) 2017-12-05
MY195824A (en) 2023-02-22
KR101583452B1 (ko) 2016-01-11
EA201791458A1 (ru) 2017-11-30
ECSP17038599A (es) 2017-09-29
WO2016122226A2 (en) 2016-08-04
UA116517C2 (uk) 2018-03-26
EP3250199A2 (en) 2017-12-06
EA032385B9 (ru) 2019-07-31
GEP20196941B (en) 2019-01-10
EA032385B1 (ru) 2019-05-31
CN107205947A (zh) 2017-09-26
CO2017006222A2 (es) 2017-09-20
KR20160094268A (ko) 2016-08-09
CL2017001680A1 (es) 2018-01-12
BR112017013857A2 (pt) 2018-02-27
CN107205947B (zh) 2020-05-22
WO2016122226A3 (en) 2016-09-15
PH12017550051A1 (en) 2018-01-29
PE20171340A1 (es) 2017-09-13
TW201639559A (zh) 2016-11-16
TWI635859B (zh) 2018-09-21
JP2018503672A (ja) 2018-02-08
SA517382016B1 (ar) 2021-03-18

Similar Documents

Publication Publication Date Title
DK2538925T3 (en) Apixabanformuleringer
JP4219988B2 (ja) 高いバイオアベイラビリティーを有するフェノフィブレート医薬組成物及びそれを調製するための方法
HRP20040323A2 (en) Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient
JP2009538912A (ja) インターロイキン−１β変換酵素阻害剤の経口制御放出剤形
TW201534357A (zh) 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
RU2716025C1 (ru) ЛЕКАРСТВЕННАЯ ФОРМА С УЛУЧШЕННЫМИ ХАРАКТЕРИСТИКАМИ pH-ЗАВИСИМОГО ВЫСВОБОЖДЕНИЯ ПРЕПАРАТА, СОДЕРЖАЩАЯ ЭЗОМЕПРАЗОЛ ИЛИ ЕГО ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМУЮ СОЛЬ
US20120141586A1 (en) Thrombin receptor antagonist and clopidogrel fixed dose tablet
JP6419347B2 (ja) 胃腸疾患治療用医薬組成物
CN109414423A (zh) 包含丙戊酸的延迟释放药物制剂和其用途
CN110063944B (zh) 一种苯磺酸左旋氨氯地平阿托伐他汀钙片及其制备方法
JP5823401B2 (ja) 不快な味が遮蔽された薬物含有膜被覆粒子
WO2014171542A1 (ja) 放出制御製剤
JP2023071921A (ja) 様々な用量のレナリドミドの経口用錠剤組成物
CN115518066A (zh) 一种用于治疗抗凝血的药物组合物及应用
EP2190419A1 (en) Multi particulate matrix system containing galantamine
CN108096251B (zh) 一种吉非替尼药物组合物及其制备方法
JP2023510140A (ja) シベンゾリンまたはその塩を含む薬学剤形
JP2022541948A (ja) エソメプラゾール及び炭酸水素ナトリウムを含む安定した薬学的組成物
JP2006257068A (ja) 高含量塩酸テルビナフィン錠剤およびその製造方法
Nicholas et al. Development and evaluation of extended release matrix tablets of Alfuzosin HCl and its comparison with marketed product
CN113226315B (zh) 一种含有肾脏钾离子外排通道抑制剂的药物组合物及其制备方法
CA2481377A1 (en) Antihistamine-decongestant pharmaceutical compositions
TWI595871B (zh) 含有兒茶酚－ｏ－甲基轉移酶抑制劑之口服醫藥組成物及其製造方法
JP2023140859A (ja) アプレミラストを含有する錠剤の製造方法、アプレミラストを含有する錠剤、及びアプレミラストを含有する錠剤の打錠性の改善方法
WO2022132978A1 (en) Modified release solid oral dosage form for once daily administration of monomethyl fumarate

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180320

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180918

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181002

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181009

R150 Certificate of patent or registration of utility model

Ref document number: 6419347

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250